Search

Your search keyword '"Srour, Samer"' showing total 886 results

Search Constraints

Start Over You searched for: Author "Srour, Samer" Remove constraint Author: "Srour, Samer"
886 results on '"Srour, Samer"'

Search Results

202. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

203. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

204. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

205. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

206. Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

207. Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

208. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies

209. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM

210. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

211. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era

212. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide‐based maintenance therapy

213. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

214. Results of a Phase I Study with Mb-IL21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Refractory Acute Myeloid Leukemia

215. Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation

216. Impact of Induction with VRD Vs. VCD on the Outcome of Patients with Multiple Myeloma after an Autologous Hematopoietic Stem Cell Transplantation

217. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 mg/m2 Conditioning, and Lenalidomide Maintenance

220. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.

222. 592 - Creatinine Clearance Is Associated with Propylene Glycol-Free Melphalan (Evomela) Pharmacokinetics and Gastrointestinal Toxicities in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

223. 540 - Impact of Gender on Outcomes of Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant

224. 532 - Single-Agent Lenalidomide Maintenance after Upfront Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma: The MD Anderson Cancer Center Experience

225. 512 - Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL)

226. 511 - Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT)

227. 515 - Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL)

228. 506 - Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant

229. 215 - Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation

230. 212 - Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation

232. 54 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

233. 38 - Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (Pano), Gemcitabine (Gem), Busulfan (Bu) and Melphalan (Mel) (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort

235. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

236. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis

237. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma

238. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation

239. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

240. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center

241. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation

242. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy

243. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation

244. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial

245. Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

246. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation

247. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

248. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience

250. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance

Catalog

Books, media, physical & digital resources